Why Shares of Novo Nordisk Stock Sank (Again) This Week

Core Insights - Novo Nordisk's shares have dropped 20% this week, marking a significant decline of 75% overall due to poor trial results for its new weight-loss drug CagriSema against Eli Lilly's Zepbound [1][2] - The company is facing increased pressure from the U.S. government, leading to announced price cuts for its weight-loss drug Wegovy in 2027, potentially reaching 50% [1][4] Company Performance - Novo Nordisk's revenue growth has stagnated at 77% over the last three years, while Eli Lilly's revenue has surged by 135%, indicating a shift in market dynamics [3] - The recent trial results showed that patients using Zepbound lost slightly more weight than those using CagriSema, contributing to Novo Nordisk's competitive disadvantage [2][3] Market Position - The weight-loss drug market is currently dominated by Eli Lilly, leaving Novo Nordisk shareholders in a challenging position as the company struggles to maintain its market share [3] - Novo Nordisk's price-to-earnings ratio is approaching 10, significantly lower than Eli Lilly's, but investor sentiment is cautious due to anticipated market share losses and price reductions [7]